| 证券代码：002287 | 证券简称：奇正藏药 | 公告编号：2025-052 | | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 西藏奇正藏药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 西藏奇正藏药股份有限公司（以下简称"公司"）于 2025 年 2 月 27 日召开 第六届董事会第九次会议，审议通过了《关于回购股份方案的议案》，同意公司 使用自有资金以集中竞价交易方式回购公司 A 股股份，回购的公司股份将用于股 权激励或员工持股计划。本次回购总金额为不低于人民币 9,000 万元（含）且不 超过人民币 16,000 万元（含），回购价格不超过 31.65 元/股（含），若按回购 总金额上、下限和回购股份价格上限测算，预计回购股份数量约为 284.36 万股 ——505.53 万股，约占公告日公司总股本的 0.5354%——0.9519%。具体回购金 额及回购数量以回购完成时实际使用的资金和回购股份数量为准。回购股份的实 施期限自董事会审议通过本次回购股份方 ...

| 证券代码：002287 | 证券简称：奇正藏药 | 公告编号：2025-053 | | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 西藏奇正藏药股份有限公司 | 信息披露义务人 | 甘肃奇正实业集团有限公司 | | --- | --- | | 住所 | 甘肃省兰州市城关区(高新开发区)张苏滩 808 号 | | 权益变动时间 | 2025 年 7 月 21 日—2025 年 7 月 31 日 | 一、本次权益变动情况 | 2025 | 年 7 月 21 日—2025 年 7 月 31 日，公司可转债累计转股 | | --- | --- | | 5,747,541 | 年 7 月 18 | | 日）增加至 | 536,984,940；公司控股股东奇正集团持股数不变， | | 股票简称 奇正藏药 | 股票代码 002287 | | 变动方向 上升□ 下降√ | 一致行动人 有√ 无□ | | 是否为第一大股东或实际控制人 | 是√ 否□ | | 股份种类（A股、B股等） | | | | 股数（万股） 比例（%） | | A 股 | 被动稀释 0.73% | ...

Market Overview - A-shares experienced a volatile trading day with the Shanghai Composite Index down 0.37%, Shenzhen Component down 0.17%, and ChiNext down 0.24% [3][4] - The total trading volume in the Shanghai and Shenzhen markets was 1.6 trillion yuan, a decrease of 337.7 billion yuan compared to the previous trading day [4] Sector Performance - The military, oil and gas, civil explosives, rare earth permanent magnets, and PCB sectors saw the largest declines [7] - Conversely, the traditional Chinese medicine sector surged, with AI applications also showing strength, while solar energy, BC batteries, education, logistics, and paper sectors performed well [7] Notable Stocks - The solar energy sector rebounded significantly, with stocks like Jiejia Weichuang and Shuangliang Energy hitting the daily limit, and Haiyou New Materials rising over 12% [7] - The traditional Chinese medicine sector saw multiple stocks hitting the daily limit, including Qizheng Tibetan Medicine and Weikang Pharmaceutical [8] Capital Flow - Main capital inflows were observed in the banking, solar equipment, and traditional Chinese medicine sectors, while textile and clothing, electric grid equipment, and gas sectors experienced net outflows [10] - Specific stocks with significant net inflows included Jiejia Weichuang (5.42 billion yuan), Beiqi Blue Valley (4.95 billion yuan), and Shuangliang Energy (4.55 billion yuan) [10] Market Sentiment and Outlook - Analysts noted that the A-share index has shown strong characteristics with three consecutive monthly gains, but August may see profit-taking and technical pressure above 3600 points [11] - Despite recent adjustments, the overall market trend remains upward, with high trading volumes providing more room for error [11] - The market is entering a medium to long-term slow bull phase, with reduced volatility and healthy rotation of market hotspots [11]

| 证券代码：002287 | 证券简称：奇正藏药 | 公告编号：2025-054 | | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 西藏奇正藏药股份有限公司 关于奇正转债可能满足赎回条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： | 证券代码：002287 | 证券简称：奇正藏药 | | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 转股价格：19.01元/股 | | 转股时间：2021年3月29日至2026年9月21日 自2025年7月21日至2025年8月1日，西藏奇正藏药股份有限公司（以下简称 "公司"）股票已有9个交易日的收盘价格不低于"奇正转债"当期转股价19.01 元/股的130%（即24.713元/股）。若在未来触发"奇正转债"的有条件赎回条款， 即公司股票在任何连续三十个交易日中至少十五个交易日的收盘价不低于当期 转股价格的130%（含130%），根据《公开发行可转换公司债券募集说明书》（以下 简称"《募集说明书》"）中有 ...

Market Overview - The market experienced a high and then a pullback, with the three major indices slightly down. The pharmaceutical sector continued its strong performance, with stocks like Qizheng Zangyao and Asia-Pacific Pharmaceutical hitting the daily limit. AI application stocks remained active, with companies like Qidi Design and Zhengzhong Design also reaching the limit. The photovoltaic sector saw a collective rebound, with stocks such as Jiejia Weichuang and Shuangliang Energy hitting the limit. Overall, more stocks rose than fell, with over 3,300 stocks in the Shanghai and Shenzhen markets showing gains, and today's trading volume was 1.62 trillion, a decrease of over 340 billion from the previous day [1]. Sector Highlights Pharmaceuticals - The pharmaceutical sector continued to surge, with Qizheng Zangyao achieving three consecutive limits, and Asia-Pacific Pharmaceutical and Fuyuan Pharmaceutical also hitting the limit. Notable stock performances include: - Qizheng Zangyao: Latest price 34.69, up 9.99%, market cap 18.389 billion [5] - Asia-Pacific Pharmaceutical: Latest price 7.40, up 9.96%, market cap 5.518 billion [6] - Fuyuan Pharmaceutical: Latest price 26.54, up 9.99%, market cap 12.739 billion [6] - Analysts believe the innovative drug sector's prosperity is sustainable, driven by policy support and increasing global competitiveness. The recovery of overseas orders and performance in the innovative drug supply chain is also noted, with expectations for a rebound in demand by 2025 [4][6]. Artificial Intelligence - The AI application sector saw significant gains, with stocks like Huanqiu Printing and Zhengzhong Design hitting the limit. Notable performances include: - Huanqiu Printing: Latest price 10.16, up 9.96%, market cap 3.252 billion [10] - Zhengzhong Design: Latest price 11.66, up 10.00%, market cap 3.301 billion [10] - Qidi Design: Latest price 16.08, up 20.00%, market cap 2.695 billion [10] - The recent strong debut of Figma on the NYSE, closing at $115.5 with a 250% increase, highlights the potential for AI-driven design tools to disrupt traditional markets [8][11]. Photovoltaics - The photovoltaic sector showed renewed strength, with stocks like Wenkai Co. and Jiejia Weichuang hitting the limit. Key stock performances include: - Wenkai Co.: Latest price 4.84, up 10.00%, market cap 2.145 billion [13] - Jiejia Weichuang: Latest price 66.19, up 20.00%, market cap 19.006 billion [12] - Jiejia Weichuang's recent earnings forecast indicates a net profit of 1.7 to 1.96 billion, representing a year-on-year growth of 38.65% to 59.85% [12]. - The Ministry of Industry and Information Technology's recent notice on energy conservation in the polysilicon industry is expected to accelerate supply-side reforms in the photovoltaic sector [12][14].

Market Overview - The total trading volume in the Shanghai and Shenzhen markets reached 1.60 trillion yuan, a decrease of 337.7 billion yuan compared to the previous trading day, with over 3,300 stocks rising across the market [1][3]. Index Performance - As of the market close on August 1, the three major A-share indices maintained a fluctuating pattern, with the Shanghai Composite Index down 0.37%, the Shenzhen Component Index down 0.17%, and the ChiNext Index down 0.24% [2]. Sector Performance - The military, oil and gas, civil explosives, rare earth permanent magnets, and PCB sectors experienced the largest declines, while the traditional Chinese medicine sector surged, and AI applications, photovoltaic, BC batteries, education, logistics, and paper-making sectors saw significant gains [5]. - The photovoltaic sector rebounded collectively, with stocks like Jiejia Weichuang and Shuangliang Energy hitting the daily limit, and Haiyou New Materials rising over 12% [5]. Stock Highlights - Notable gainers in the traditional Chinese medicine sector included Qizheng Tibetan Medicine, Weikang Pharmaceutical, Tianmu Pharmaceutical, and Xintian Pharmaceutical, all reaching the daily limit [5][6]. - Specific stocks with significant increases included: - Shengtai Biological: +23.15% at 13.99 yuan - Weikang Pharmaceutical: +20.00% at 25.62 yuan - Xinguang Pharmaceutical: +12.76% at 19.80 yuan [6]. Capital Flow - Main capital inflows were observed in the banking, photovoltaic equipment, and traditional Chinese medicine sectors, while textile and apparel, electric grid equipment, and gas sectors saw net outflows [7]. - Individual stocks with notable net inflows included Jiejia Weichuang, Beiqi Blue Valley, and Shuangliang Energy, with net inflows of 542 million yuan, 495 million yuan, and 455 million yuan respectively [8]. Institutional Insights - According to Dexun Securities, the A-share index shows a strong characteristic of three consecutive monthly gains, indicating significant profit accumulation, with potential for profit-taking and technical pressure around the 3,600-point mark in August [9]. - Guojin Securities noted that while the market is in a period of emotional decline, the current rally is not over, as the weekly trend remains upward and trading volume is high, providing more room for error [9]. - Dongxing Securities suggested that the Chinese stock market has entered a medium to long-term slow bull phase, with reduced volatility and healthy rotation of market hotspots, recommending a high position with a focus on sectors with good economic prospects [9].

Group 1 - A-shares experienced significant market activity on August 1, with 49 stocks hitting the daily limit up and 9 stocks hitting the limit down [1] - The traditional Chinese medicine sector showed strong performance, with stocks like Qizheng Zangyao achieving three consecutive limit ups, and Guizhou Bailing achieving two consecutive limit ups [1] - The smart parking concept also gained traction, highlighted by Dongjie Intelligent hitting the limit up [1] Group 2 - Among the stocks with consecutive limit ups, *ST Yatai achieved four limit ups in seven days, while Honghe Technology and Tianfu Culture Tourism achieved three limit ups in five days [1] - Other notable stocks include *ST Yazhen and Shengtong Energy with three consecutive limit ups, and Fuyuan Pharmaceutical with two limit ups over four days [1] - Conversely, Huaci Co. and Poly United faced consecutive limit downs for two days, while *ST Suwu and Dalian Friendship also hit the limit down [1]

(责任编辑：宋政 HN002) 格隆汇8月1日｜A股市场中药股逆势上涨，其中，生物谷涨近25%，维康药业20CM涨停，新光药业 (300519)涨13%，大唐药业涨近11%，天目药业(600671)、新天药业(002873)、太龙药业(600222)、奇正 藏药(002287)、贵州百灵(002424)10CM涨停，众生药业(002317)涨超8%，亚宝药业(600351)、沃华医药 (002107)涨超6%。 | 代码 | 名称 | 涨幅% ↓ | 总市值 | 年初至今涨幅%。 | | --- | --- | --- | --- | --- | | 833266 | 生物谷 | 24.91 | 17.60亿 | 51.12 | | 300878 | 维康药业 | 20.00 | 37.10亿 | 71.51 | | 300519 | 新光药业 | 13.04 | 31.76亿 | 52.71 | | 836433 | 大唐药业 | 10.76 | 22.14亿 | 42.65 | | 600671 | 天目药业 | 10.03 | 18.71亿 | 74.94 | | 002873 | 新天药业 | 10. ...

MACD金叉信号形成，这些股涨势不错！ 格隆汇8月1日｜A股市场中药股逆势上涨，其中，生物谷（维权）涨近25%，维康药业（维权）20CM 涨停，新光药业涨13%，大唐药业涨近11%，天目药业、新天药业、太龙药业、奇正藏药、贵州百灵 （维权）10CM涨停，众生药业涨超8%，亚宝药业、沃华医药（维权）涨超6%。 | 代码 | 名称 | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | | 833266 | 生物谷 | 24.91 | 17.60亿 | 51.12 | | 300878 | 维康药业 | 20.00 | 37.10亿 | 71.51 | | 300519 | 新光药业 | 13.04 | 31.76 乙 | 52.71 | | 836433 | 大唐药业 | 10.76 | 22.14亿 | 42.65 | | 600671 | 天目药业 | 10.03 | 18.71亿 | 74.94 | | 002873 | 新天药业 | 10.03 | 29.19亿 | 27.68 | | 600222 | 太龙药业 | 10.00 | 39.14 ...

Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the A-share listed companies, 1,144 secretaries earned over 1 million yuan annually, accounting for over 21% [1] - The age distribution of secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] Group 2 - The educational background of secretaries indicates that 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's degree or higher [3] - Only three secretaries hold a doctoral degree, specifically from Yiling Pharmaceutical, Kunming Pharmaceutical Group, and Jinhua Co., Ltd. [3] Group 3 - The average annual salary of secretaries in A-share listed Chinese medicine companies is 742,400 yuan, with 39% earning below 500,000 yuan, 42% earning between 500,000 and 1 million yuan, and 15% earning between 1 million and 2 million yuan [5] - The top five highest-paid secretaries are from China Resources Sanjiu, Jichuan Pharmaceutical, Tianjin Pharmaceutical, Yiling Pharmaceutical, and Yibai Pharmaceutical, with salaries ranging from 1.3935 million to 2.5587 million yuan [7] Group 4 - There is significant variation in the number of investor receptions among listed companies, with 59% receiving fewer than 10 times a year, while 3% received between 300 and 1,000 times [9] - The five companies with the highest number of investor receptions are Zoli Pharmaceutical, Qizheng Pharmaceutical, Yunnan Baiyao, Jinghua Pharmaceutical, and Pianzihuang, with receptions ranging from 207 to 410 times [9]